

How to submit an adjustment for 2020 Financial Reporting



innovative
medicines
initiative

SOFIA:

Submission OF Information Application



innovative
medicines
initiative

SOFIA: Submission OF Information Application

Home Sofia Application

My Workspace

Call Admin

Project Admin

Project Reports

Interim Review Admin

Public Area



Helpdesk

Print

mariana.gameiro@pfizer.com

Sofia Application / My Workspace / My Calls

My Calls

← 1.

The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients.

[Specific Privacy Statement](#) | SOFIA: **S**ubmission **O**F Information **A**pplication, Copyright © 2021 IMI.

v.3.0 (build 077)

Note: SOFIA link <https://sofia.imi.europa.eu/>



- 🏠 Sofia Application
- 📁 My Workspace ▾
- 🏛️ Call Admin ▾
- 💻 Project Admin ▾
 - Periodic Report Overview
 - Summary Financial Report
 - IMI2 EFPIA Annual Report – Project Overview
 - IMI2 EFPIA Annual Report – SGG Overview
 - IMI2 EFPIA Annual Report – Company Overview
 - IMI2 EFPIA Periodic Report Submission**



🏠 [Sofia Application](#) / [My Workspace](#) / [My Calls](#)

My Calls

The **Innovative Medicines Initiative (IMI)** is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients.
[Specific Privacy Statement](#) | SOFIA: **S**ubmission **O**F Information **A**pplication, Copyright © 2021 IMI.
v.3.0 (build 077)



Sofia Application

My Workspace

Call Admin

Project Admin

Periodic Report Overview

Summary Financial Report

IMI2 EFPIA Annual Report –
Project Overview

IMI2 EFPIA Annual Report – SGG
Overview

IMI2 EFPIA Annual Report –
Company Overview

IMI2 EFPIA Periodic Report
Submission

Project Details

IMI OPS Overview

Project Reports

Interim Review Admin



Helpdesk

Print

mariana.gameiro@pfizer.com

Sofia Application / Project Admin / IMI2 EFPIA Periodic Report Submission

IMI2 EFPIA Periodic Report Submission

Export to Excel by Company

Export to Excel by Project

Reporting Period: 6 - 01/01/2020-31/12/2020

Document: None

3.



6 - 01/01/2020-31/12/2020

5 - 01/01/2019-31/12/2019

4 - 01/01/2018-31/12/2018

3 - 01/01/2017-31/12/2017

2 - 01/01/2016-31/12/2016

1 - 01/07/2014-31/12/2015

The Innovative Medicines
Specific Privacy State
v.3.0 (build 077)

largest public-private initiative aiming to speed up the development of better and safer medicines for patients.
Information Application, Copyright © 2021 IMI.



- Sofia Application
- My Workspace
- Call Admin
- Project Admin
 - Periodic Report Overview
 - Summary Financial Report
 - IMI2 EFPIA Annual Report – Project Overview
 - IMI2 EFPIA Annual Report – SGG Overview
 - IMI2 EFPIA Annual Report – Company Overview
 - IMI2 EFPIA Periodic Report Submission
 - Project Details
 - IMI OPS Overview
- Project Reports
- Interim Review Admin



Sofia Application / Project Admin / IMI2 EFPIA Periodic Report Submission

IMI2 EFPIA Periodic Report Submission

Export to Excel by Company

Export to Excel by Project

Reporting Period: 6 - 01/01/2020-31/12/2020

Document: None

- None
- Financial Statement
- Adjustment to 2019
- Adjustment to 2018
- Adjustment to 2017
- Adjustment to 2016
- Adjustment to 2015

4.

The Innovative Medicines Initiative (IMI) is Europe's largest public-private partnership to speed up the development of better and safer medicines for patients. Specific Privacy Statement | SOFIA: Submission OF Information Applications to IMI. v.3.0 (build 077)





Sofia Application

My Workspace

Call Admin

Project Admin

Periodic Report Overview

Summary Financial Report

IMI2 EFPIA Annual Report –
Project Overview

IMI2 EFPIA Annual Report – SGG
Overview

IMI2 EFPIA Annual Report –
Company Overview

IMI2 EFPIA Periodic Report
Submission



Helpdesk

Print

mariana.gameiro@pfizer.com

Sofia Application / Project Admin / IMI2 EFPIA Periodic Report Submission

IMI2 EFPIA Periodic Report Submission

Export to Excel by Company

Export to Excel by Project

Reporting Period: 6 - 01/01/2020-31/12/2020

Document: Adjustment to 2019

PIC	Legal Name	Annex 4	Uploaded financial statement	Uploaded IMI2 Certification
998133396	PFIZER LIMITED SANDWICH United Kingdom	View Edit		

5.

Print aggregated PDF for all organisations

Value of contribution (in €)						
#	Project/Advisory Group	Value of in-kind contribution in EU and H2020 associated countries	Financial contribution (FC) to recipients in EU and H2020 associated countries	Value of NON EU contribution coming from Third Countries	TOTAL Value of contribution	IMI accepted in kind
		(a)	(b)	(c)	(a)+(b)+(c)	
1	3TR	0.00	0.00	0.00	0.00	0.00
2	ARDAT	0.00	0.00	0.00	0.00	0.00
3	BIOMAP	0.00	0.00	0.00	0.00	0.00
4	c4c	0.00	0.00	0.00	0.00	0.00
5	CARE	0.00	0.00	0.00	0.00	0.00
6	COMBACTE-CDI	0.00	0.00	0.00	0.00	0.00
7	ConcePTION	0.00	0.00	0.00	0.00	0.00
8	DO-IT	0.00	0.00	0.00	0.00	0.00
9	EBiSC2	0.00	0.00	0.00	0.00	0.00
10	EFOEUPATI	0.00	0.00	0.00	0.00	0.00

6. 

Note: On this page, it will appear all the IMI2 projects that could have adjustments to 2019 reporting

IMI 2 certification Latest Certification Document:

(a) COST

Cost categories	in €	Short description
<p>A1. Personnel costs – Direct personnel costs declared as actual cost (Total personnel costs, EU and non-EU)</p> <p><i>Please specify:</i></p> <ul style="list-style-type: none">- Average FTE rate or Person Months for the concerned year:- List of related WP(s):	<p>7. → 0.00</p>	<p>EXAMPLE:</p> <ul style="list-style-type: none">- Average FTE rate or Person Months for the concerned year: 2.1 PMs- List of related WP(s): General, WP1, WP4, WP6 <p>(1858 characters remaining)</p>
<p>B1. Subcontracting costs - Total subcontracting costs, EU and non-EU</p> <p><i>Please specify:</i></p> <ul style="list-style-type: none">- Brief description of subcontracted task and related WP:- Vendor name, if possible:- Is it foreseen in the DoA (Annex 1)? Y/N- If not, is it a new task (not already described in Annex 1)? Y/N	<p>7. → 0.00</p>	<p>EXAMPLE:</p> <ul style="list-style-type: none">- Brief description of subcontracted task and related WP:- Vendor name, if possible:- Is it foreseen in the DoA (Annex 1)? Y/N- If not, is it a new task (not already described in Annex 1)? Y/N <p>(2000 characters remaining)</p>
<p>C1. Other direct costs – Total, EU and non-EU</p> <p><i>Please provide a brief description of the cost</i></p>	<p>7. → 0.00</p>	<p>EXAMPLE:</p> <ul style="list-style-type: none">- Please provide a brief description of the cost:

D1. Indirect costs (according to usual accounting practices and if not included in A and C) – Total, EU and non-EU

7. 

(2000 characters remaining)

E1. Value of in kind contribution, EU and non-EU.

7. 

(2000 characters remaining)


IMI accepted costs

7. 

(2000 characters remaining)

Non-EU In kind contribution

Cost categories	in €	Short description
-----------------	------	-------------------

Non-EU in kind: did you provide in kind contribution from outside a Member State or an H2020 Associated country? Yes No  7.

(1946 characters remaining)

If yes, please provide amount of non-EU in kind contribution

7. 

Please specify:
- Is it in line with the estimated budget (Annex 2)? Y/N
- If not, please provide an explanation



(b) Financial Contribution (FC)

Name and country of Beneficiary

Total

7. 

Please specify:

- Name of recipient
- Is it foreseen in the DoA (Annex 1)? Y/N
- If not, is the task to be carried-out by the recipient already described in the DoA (Annex 1)? Y/N

EXAMPLE:

- Name of recipient: **UPM**
- Is it foreseen in the DoA (Annex 1)? **Y**
- If not, is the task to be carried-out by the recipient already described in the DoA (Annex 1)? Y/N

(2000 characters remaining)

Add new Financial Contribution

(c) Summary table – total in kind

	Declared	IMI Accepted
Value of in kind contribution in EU and H2020 associated countries	<input type="text" value="0.00"/>	<input type="text" value="0.00"/>
Financial contribution	<input type="text" value="0.00"/>	<input type="text" value="0.00"/>
Value of in kind contribution <u>OUTSIDE</u> EU and H2020 associated countries	<input type="text" value="0.00"/>	<input type="text" value="0.00"/>
Total value of in kind contribution	<input type="text" value="0.00"/>	<input type="text" value="0.00"/>

8. 

The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients.

Note: Repeat steps 6, 7 and 8 for all the projects that need reporting

Name of the Auditor

Is there a Certification by an independent auditor attached to this financial statement?

Yes No **9.**

Name of the Auditor

Name of the Person(s) authorized to sign this document

10.

Signed Financial Statement

Version

Signed Financial Statement Document

Upload Date

Upload New Signed Financial Statement

Choose file

Upload

Suggested file naming convention [EFPIA company]_[year]_Financial Statement.pdf

Actors

FIA: Financial Initiating Agent

FVA: Financial Verification Agent

Cancel

Save&Continue

Save

Finalize

Print to PDF

Print to PDF IMI Acceptance

11.

Note: This view will appear in the bottom of the page shown in slide 7 – step 6

Signed Financial Statement

Version	Signed Financial Statement Document	Upload Date
---------	-------------------------------------	-------------

Upload New Signed Financial Statement

Choose file

Upload

Suggested file naming convention [EFPIA company]_[year]_Financial Statement.pdf

Actors

FIA: Financial Initiating Agent

FVA: Financial Verification Agent

Cancel

Reopen

Print to PDF

Print to PDF IMI Acceptance



The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients.

[Specific Privacy Statement](#) | SOFIA: **S**ubmission **O**F **I**nformation **A**pplication, Copyright © 2021 IMI.

v.3.0 (build 077)

Note: Sign the Form C that has been printed to PDF

Signed Financial Statement

Version	Signed Financial Statement Document	Upload Date
---------	-------------------------------------	-------------

Upload New Signed Financial Statement

Suggested file naming convention [EFPIA company]_[year]_Financial Statement.pdf

Choose file

Upload



Actors

FIA: Financial Initiating Agent

FVA: Financial Verification Agent

Cancel

Reopen

Print to PDF

Print to PDF IMI Acceptance

The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients.

[Specific Privacy Statement](#) | SOFIA: **S**ubmission **O**F Information **A**pplication, Copyright © 2021 IMI.

v.3.0 (build 077)



Note: Select the already signed Form C on step 13 and upload it into SOFIA on step 14

Signed Financial Statement

Version	Signed Financial Statement Document	Upload Date
---------	-------------------------------------	-------------

V1	[EFPIA company name]_2020_Adjustment_2019_Financial Statement.pdf	22/03/2021	Delete
----	---	------------	--------

Upload New Signed Financial Statement

Choose file

Upload

Suggested file naming convention [EFPIA company]_[year]_Financial Statement.pdf

Actors

FIA: Financial Initiating Agent

FVA: Financial Verification Agent

Cancel

Reopen

Print to PDF

Print to PDF IMI Acceptance

The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients.

[Specific Privacy Statement](#) | SOFIA: **S**ubmission **O**F **I**nformation **A**pplication, Copyright © 2021 IMI.

v.3.0 (build 077)

Note: Adjustment to 2019 reporting complete